中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9

文献类型：期刊论文

作者Li, Hui-hui1,2; Li, Jun1,2; Zhang, Xian-jing1,2; Li, Jiao-meng1,2; Xi, Cong1,2; Wang, Wen-qiong1,2; Lu, You-li3,4; Xuan, Li-jiang1,2
刊名ACTA PHARMACOLOGICA SINICA
出版日期2020-03-01
卷号41期号:3页码:327-335
关键词23,24-dihydrocucurbitacin B lipid-lowering agent LDLR PCSK9 HNF1 alpha SREBP2
ISSN号1671-4083
DOI10.1038/s41401-019-0274-0
通讯作者Xuan, Li-jiang(ljxuan@simm.ac.cn)
英文摘要23,24-Dihydrocucurbitacin B (designated as C95 in this article) is a cucurbitane triterpenoid that has been shown to possess a variety of pharmacological activities, such as anti-inflammatory and anti-HIV-1 activities etc. In this study, we investigated the effects of 23,24-dihydrocucurbitacin B on lipid regulation. We showed that 23,24-dihydrocucurbitacin B (1-5 mu M) dose-dependently promoted DiI-LDL uptake in HepG2 cells by upregulating low-density lipoprotein receptor (LDLR) protein. In HepG2 cells, 23,24-dihydrocucurbitacin B (1-10 mu M) dose-dependently enhanced LDLR promoter activity by elevating the mature form of SREBP2 (sterol regulatory element binding protein 2) protein levels on one hand, and inhibited PCSK9 (proprotein convertase subtilisin/kexin type 9) promoter activity by attenuating HNF1 alpha (hepatocyte nuclear factor-1 alpha) protein levels in nuclei on the other hand. Consequently, the expression of LDLR protein markedly increased, whereas the PCSK9-mediated LDLR protein degradation decreased. In a high-cholesterol LVG golden Syrian Hamster model, administration of 23,24-dihydrocucurbitacin B (30 mg . kg(-1). d(-1), intragastric, for 3 weeks) significantly decreased the serum LDL-cholesterol (LDL-C) levels. PCSK9 protein levels in the serum and liver tissues were significantly decreased, whereas LDLR protein levels in liver tissues were significantly increased in the treated animals as compared with the control animals. In conclusion, our study demonstrates for the first time that 23,24-dihydrocucurbitacin B exhibits dual transcriptional regulation of LDLR and PCSK9 in HepG2 cells by increasing SREBP2 protein levels and decreasing HNF1 alpha protein levels in the nuclei. These results propose a new strategy to simultaneously manage LDLR and PCSK9 protein expression and provide a promising lead compound for drug development.
WOS关键词DIHYDROCUCURBITACIN-B ; RECEPTOR ; CHOLESTEROL ; HYPERCHOLESTEROLEMIA ; EXPRESSION ; APOPTOSIS
资助项目Drug Innovation Major Project of China[2018ZX09735001-002-005] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12040335] ; National Natural Science Foundation of China[81773863] ; Youth Innovation Promotion Association
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000514159600005
出版者NATURE PUBLISHING GROUP
源URL[http://119.78.100.183/handle/2S10ELR8/281431]  
专题新药研究国家重点实验室
通讯作者Xuan, Li-jiang
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Zhongshan Xuhui Hosp, Shanghai Xuhui Cent Hosp, Shanghai 200031, Peoples R China
4.Chinese Acad Sci, Shanghai Clin Res Ctr, Shanghai 200031, Peoples R China
推荐引用方式
GB/T 7714		 Li, Hui-hui,Li, Jun,Zhang, Xian-jing,et al. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9[J]. ACTA PHARMACOLOGICA SINICA,2020,41(3):327-335.
APA Li, Hui-hui.,Li, Jun.,Zhang, Xian-jing.,Li, Jiao-meng.,Xi, Cong.,...&Xuan, Li-jiang.(2020).23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.ACTA PHARMACOLOGICA SINICA,41(3),327-335.
MLA Li, Hui-hui,et al."23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9".ACTA PHARMACOLOGICA SINICA 41.3(2020):327-335.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。